Feed:All articles/Pretty: Difference between revisions

Jump to navigation Jump to search

Feed:All articles/Pretty (view source)

Revision as of 20:25, 19 June 2025

17,029 bytes removed ,  19 June
no edit summary
No edit summary
Tag: Manual revert
No edit summary
Line 726: Line 726:
         },
         },
         {
         {
             "timestamp" : "2025-02-27T18:59:21Z",
             "timestamp" : "2025-06-19T18:32:30Z",
             "briefDesignDescription" : "Combination of ambrisentan & tadalafil vs monotherapy in PAH",
             "briefDesignDescription" : "Combination of ambrisentan & tadalafil vs monotherapy in PAH",
             "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1413687",
             "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1413687",
Line 739: Line 739:
             "published" : "2015-08-27",
             "published" : "2015-08-27",
             "pageName" : "AMBITION",
             "pageName" : "AMBITION",
             "diseases" : "Pulmonary hypertension",
             "diseases" : "Pulmonary Hypertension",
             "abbreviation" : "AMBITION",
             "abbreviation" : "AMBITION",
             "title" : "Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension",
             "title" : "Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension",
Line 1,125: Line 1,125:
         },
         },
         {
         {
             "timestamp" : "2024-08-29T18:49:50Z",
             "timestamp" : "2025-06-19T18:36:44Z",
             "briefDesignDescription" : "Zanubrutinib vs. ibrutinib in WM",
             "briefDesignDescription" : "Zanubrutinib vs. ibrutinib in WM",
             "fulltexturl" : "https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs",
             "fulltexturl" : "https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs",
Line 1,138: Line 1,138:
             "published" : "2020-10-29",
             "published" : "2020-10-29",
             "pageName" : "ASPEN",
             "pageName" : "ASPEN",
             "diseases" : "Waldenström Macroglobulinemia",
             "diseases" : "Waldenström Macroglobulinemia;Lymphoma",
             "abbreviation" : "ASPEN",
             "abbreviation" : "ASPEN",
             "title" : "ASPEN",
             "title" : "ASPEN",
Line 1,332: Line 1,332:
             "title" : "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation",
             "title" : "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation",
             "pmid" : "30883055"
             "pmid" : "30883055"
        },
        {
            "timestamp" : "2018-12-20T20:31:01Z",
            "briefDesignDescription" : "Rosuvastatin in ESRD",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0810177",
            "pageid" : 2390,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810177",
            "trainingLevel" : "Resident",
            "citation" : "Fellstrom BC, <i>et al</i>. \"Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis\". <i>The New England Journal of Medicine</i>. 2009. 360(14):1395-1407.",
            "subspecialties" : "Cardiology;Nephrology",
            "expansion" : "A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events",
            "statusUsableDate" : "2018-12-20",
            "briefResultsDescription" : "No difference in number of cardiovascular events",
            "published" : "2009-04-02",
            "pageName" : "AURORA",
            "diseases" : "Cardiovascular Disease;Myocardial Infarction;Stroke",
            "abbreviation" : "AURORA",
            "title" : "Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis",
            "pmid" : "19332456"
         },
         },
         {
         {
Line 2,092: Line 2,073:
             "title" : "Clopidogrel with aspirin in acute minor stroke or transient ischemic attack",
             "title" : "Clopidogrel with aspirin in acute minor stroke or transient ischemic attack",
             "pmid" : "23803136"
             "pmid" : "23803136"
        },
        {
            "timestamp" : "2018-03-08T18:57:50Z",
            "briefDesignDescription" : "Aspirin/clopidogrel vs. aspirin for CV prevention",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa060989",
            "pageid" : 2175,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa060989",
            "trainingLevel" : "Resident",
            "citation" : "Bhatt DL, <i>et al</i>. \"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events\". <i>The New England Journal of Medicine</i>. 2006. 354(16):1706-1717.",
            "subspecialties" : "Cardiology",
            "expansion" : "Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance",
            "statusUsableDate" : "2014-10-01",
            "briefResultsDescription" : "Combination therapy no better than aspirin alone, more bleeding",
            "published" : "2006-04-20",
            "pageName" : "CHARISMA",
            "diseases" : "Cardiovascular Disease;Stroke;Myocardial Infarction;Acute Coronary Syndrome",
            "abbreviation" : "CHARISMA",
            "title" : "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events",
            "pmid" : "16531616"
         },
         },
         {
         {
Line 2,491: Line 2,453:
             "title" : "Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure",
             "title" : "Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure",
             "pmid" : "12390947"
             "pmid" : "12390947"
        },
        {
            "timestamp" : "2019-11-07T19:27:29Z",
            "briefDesignDescription" : "Stenting vs. medical therapy in RAS",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1310753",
            "pageid" : 2388,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310753",
            "trainingLevel" : "Intern",
            "citation" : "Cooper CJ, <i>et al</i>. \"Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis\". <i>The New England Journal of Medicine</i>. 2014. 370(1):13-22.",
            "subspecialties" : "Nephrology;Cardiology",
            "expansion" : "Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis",
            "statusUsableDate" : "2019-11-07",
            "briefResultsDescription" : "No difference in clinical outcomes",
            "published" : "2014-01-02",
            "pageName" : "CORAL",
            "diseases" : "Cardiovascular Disease;Chronic Kidney Disease;Hypertension",
            "abbreviation" : "CORAL",
            "title" : "Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis",
            "pmid" : "24245566"
         },
         },
         {
         {
Line 3,840: Line 3,783:
             "title" : "Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients",
             "title" : "Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients",
             "pmid" : "30883053"
             "pmid" : "30883053"
        },
        {
            "timestamp" : "2017-12-03T22:35:28Z",
            "briefDesignDescription" : "Cinacalcet in ESRD",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205624",
            "pageid" : 2426,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205624",
            "trainingLevel" : "Resident",
            "citation" : "Chertow GM, <i>et al</i>. \"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis\". <i>The New England Journal of Medicine</i>. 2012. 367(26):2482-2494.",
            "subspecialties" : "Nephrology",
            "expansion" : "Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis",
            "statusUsableDate" : "2015-10-01",
            "briefResultsDescription" : "Cinecalcet did not reduce CV events in ESRD",
            "published" : "2012-12-27",
            "pageName" : "EVOLVE",
            "diseases" : "Chronic Kidney Disease;Cardiovascular Disease",
            "abbreviation" : "EVOLVE",
            "title" : "Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis",
            "pmid" : "23121374"
         },
         },
         {
         {
Line 4,108: Line 4,032:
         },
         },
         {
         {
             "timestamp" : "2024-10-03T17:48:57Z",
             "timestamp" : "2025-06-19T18:32:02Z",
             "briefDesignDescription" : "High-flow oxygen in respiratory failure",
             "briefDesignDescription" : "High-flow oxygen in respiratory failure",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1503326",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1503326",
Line 4,115: Line 4,039:
             "trainingLevel" : "Intern",
             "trainingLevel" : "Intern",
             "citation" : "Frat JP, <i>et al</i>. \"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure\". <i>The New England Journal of Medicine</i>. 2015. 372(23):2185-2196.",
             "citation" : "Frat JP, <i>et al</i>. \"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure\". <i>The New England Journal of Medicine</i>. 2015. 372(23):2185-2196.",
             "subspecialties" : "Pulmonology;Critical Care Medicine",
             "subspecialties" : "Pulmonology;Critical Care",
             "expansion" : "",
             "expansion" : "",
             "statusUsableDate" : "2012-03-01",
             "statusUsableDate" : "2012-03-01",
Line 4,121: Line 4,045:
             "published" : "2015-06-04",
             "published" : "2015-06-04",
             "pageName" : "FLORALI",
             "pageName" : "FLORALI",
             "diseases" : "Hypoxemic Respiratory Failure",
             "diseases" : "Respiratory Failure",
             "abbreviation" : "FLORALI",
             "abbreviation" : "FLORALI",
             "title" : "High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure",
             "title" : "High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure",
Line 4,467: Line 4,391:
             "title" : "A phase 3 randomized trial of voxelotor in sickle cell disease",
             "title" : "A phase 3 randomized trial of voxelotor in sickle cell disease",
             "pmid" : "31199090"
             "pmid" : "31199090"
        },
        {
            "timestamp" : "2019-09-20T14:01:16Z",
            "briefDesignDescription" : "Statin, BP meds, both, or neither for CVD 1° prevention",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1600177",
            "pageid" : 2770,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1600177",
            "trainingLevel" : "Resident",
            "citation" : "Yusuf S, <i>et al</i>. \"Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease\". <i>The New England Journal of Medicine</i>. 2016. 374(21):2032-2343.",
            "subspecialties" : "Cardiology",
            "expansion" : "Heart Outcomes Prevention Evaluation-3",
            "statusUsableDate" : "2019-09-19",
            "briefResultsDescription" : "Statins lower events but BP meds don't.",
            "published" : "2016-05-26",
            "pageName" : "HOPE-3",
            "diseases" : "Cardiovascular Disease",
            "abbreviation" : "HOPE-3",
            "title" : "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease",
            "pmid" : "27039945"
         },
         },
         {
         {
Line 4,524: Line 4,429:
             "title" : "Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial",
             "title" : "Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial",
             "pmid" : "29153975"
             "pmid" : "29153975"
        },
        {
            "timestamp" : "2020-02-06T19:36:49Z",
            "briefDesignDescription" : "Simvastatin in high risk for CVD",
            "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(02)09327-3",
            "pageid" : 2696,
            "pdfurl" : "",
            "trainingLevel" : "Student",
            "citation" : "Heart Protection Study Collaborative Group Writers. \"MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial\". <i>The Lancet</i>. 2002. 360(9326):7-22.",
            "subspecialties" : "Cardiology",
            "expansion" : "Heart Protection Study Statin Arm",
            "statusUsableDate" : "2020-02-07",
            "briefResultsDescription" : "Simvastatin reduces CVD events and death",
            "published" : "2002-06-06",
            "pageName" : "HPS Statin",
            "diseases" : "Hyperlipidemia;Cardiovascular Disease",
            "abbreviation" : "HPS",
            "title" : "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial",
            "pmid" : "12114036"
         },
         },
         {
         {
Line 4,792: Line 4,678:
         },
         },
         {
         {
             "timestamp" : "2019-03-27T18:27:05Z",
             "timestamp" : "2025-06-19T18:33:35Z",
             "briefDesignDescription" : "Early vs. delayed RRT in septic shock",
             "briefDesignDescription" : "Early vs. delayed RRT in septic shock",
             "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1803213",
             "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1803213",
Line 4,805: Line 4,691:
             "published" : "2018-10-11",
             "published" : "2018-10-11",
             "pageName" : "IDEAL-ICU",
             "pageName" : "IDEAL-ICU",
             "diseases" : "Acute Kidney Injury;Septic Shock",
             "diseases" : "Acute Kidney Injury;Shock;Sepsis",
             "abbreviation" : "IDEAL-ICU",
             "abbreviation" : "IDEAL-ICU",
             "title" : "Timing of renal-replacement therapy in patients with acute kidney injury and sepsis",
             "title" : "Timing of renal-replacement therapy in patients with acute kidney injury and sepsis",
Line 5,132: Line 5,018:
             "title" : "Left atrial appendage occlusion during cardiac surgery to prevent stroke",
             "title" : "Left atrial appendage occlusion during cardiac surgery to prevent stroke",
             "pmid" : "33999547"
             "pmid" : "33999547"
        },
        {
            "timestamp" : "2023-11-22T21:21:50Z",
            "briefDesignDescription" : "Liraglutide and CVD endpoints in T2DM",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1603827",
            "pageid" : 2803,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603827",
            "trainingLevel" : "Resident",
            "citation" : "Marso SP, <i>et al</i>. \"Liraglutide and cardiovascular outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2016. 375(4):311-322.",
            "subspecialties" : "Cardiology;Endocrinology",
            "expansion" : "Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results",
            "statusUsableDate" : "2016-09-01",
            "briefResultsDescription" : "Liraglutide reduces CV mortality in T2DM",
            "published" : "2016-06-28",
            "pageName" : "LEADER",
            "diseases" : "Diabetes Mellitus;Cardiovascular Disease",
            "abbreviation" : "LEADER",
            "title" : "Liraglutide and cardiovascular outcomes in type 2 diabetes",
            "pmid" : "27295427"
         },
         },
         {
         {
Line 5,208: Line 5,075:
             "title" : "Intensive Insulin Therapy in Critically Ill Patients",
             "title" : "Intensive Insulin Therapy in Critically Ill Patients",
             "pmid" : "11794168"
             "pmid" : "11794168"
        },
        {
            "timestamp" : "2024-04-02T17:35:36Z",
            "briefDesignDescription" : "ARB vs. B-blocker in HTN with LVH",
            "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08089-3/abstract",
            "pageid" : 2439,
            "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(02)08089-3.pdf",
            "trainingLevel" : "Student",
            "citation" : "Dahlof B, <i>et al</i>. \"Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE)\". <i>The Lancet</i>. 2002. 359:995-1003.",
            "subspecialties" : "Nephrology",
            "expansion" : "Cardiovvascular Morbidity and Mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol",
            "statusUsableDate" : "2024-03-29",
            "briefResultsDescription" : "Losartan lowers stroke, MI, or CVD mortality vs. atenolol in HTN with LVH",
            "published" : "2002-03-23",
            "pageName" : "LIFE",
            "diseases" : "Hypertension;Cardiovascular Disease;Stroke",
            "abbreviation" : "LIFE",
            "title" : "Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE)",
            "pmid" : "11937178"
         },
         },
         {
         {
Line 5,286: Line 5,134:
         },
         },
         {
         {
             "timestamp" : "2017-12-03T22:37:21Z",
             "timestamp" : "2025-06-19T18:33:56Z",
            "briefDesignDescription" : "Weight loss and exercise in T2DM",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1212914",
            "pageid" : 1546,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212914",
            "trainingLevel" : "Intern",
            "citation" : "Wing RR, <i>et al</i>. \"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2013. 369(2):145-154.",
            "subspecialties" : "Endocrinology;Cardiology",
            "expansion" : "Look Action for HEAlth in Diabetes",
            "statusUsableDate" : "2013-09-01",
            "briefResultsDescription" : "No reduction of CVD with weight loss and exercise in T2DM",
            "published" : "2013-07-11",
            "pageName" : "Look AHEAD",
            "diseases" : "Diabetes Mellitus;Cardiovascular Disease",
            "abbreviation" : "Look AHEAD",
            "title" : "Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes",
            "pmid" : "23796131"
        },
        {
            "timestamp" : "2023-11-09T19:05:49Z",
             "briefDesignDescription" : "Vitamin C in sepsis",
             "briefDesignDescription" : "Vitamin C in sepsis",
             "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2200644",
             "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2200644",
Line 5,318: Line 5,147:
             "published" : "2022-06-23",
             "published" : "2022-06-23",
             "pageName" : "LOVIT",
             "pageName" : "LOVIT",
             "diseases" : "Septic Shock",
             "diseases" : "Sepsis;Shock",
             "abbreviation" : "LOVIT",
             "abbreviation" : "LOVIT",
             "title" : "Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit",
             "title" : "Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit",
Line 6,234: Line 6,063:
             "title" : "Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer",
             "title" : "Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer",
             "pmid" : "10922420"
             "pmid" : "10922420"
        },
        {
            "timestamp" : "2017-12-03T22:38:00Z",
            "briefDesignDescription" : "Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801317",
            "pageid" : 1776,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801317",
            "trainingLevel" : "Resident",
            "citation" : "Yusuf S, <i>et al</i>. \"Telmisartan, ramipril, or both in patients at high risk for vascular events\". <i>The New England Journal of Medicine</i>. 2008. 358(15):1547-1559.",
            "subspecialties" : "Cardiology;Nephrology;Endocrinology",
            "expansion" : "Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial",
            "statusUsableDate" : "2014-05-01",
            "briefResultsDescription" : "No difference in CV complications, combination ACE-inhibitor and ARB poorly tolerated",
            "published" : "2008-04-10",
            "pageName" : "ONTARGET",
            "diseases" : "Cardiovascular Disease;Diabetes Mellitus;Stroke",
            "abbreviation" : "ONTARGET",
            "title" : "Telmisartan, ramipril, or both in patients at high risk for vascular events",
            "pmid" : "18378520"
         },
         },
         {
         {
Line 6,310: Line 6,120:
             "title" : "Percutaneous coronary intervention in stable angina",
             "title" : "Percutaneous coronary intervention in stable angina",
             "pmid" : "29103656"
             "pmid" : "29103656"
        },
        {
            "timestamp" : "2017-12-03T22:38:03Z",
            "briefDesignDescription" : "Fish oil for high-risk CVD",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1203859",
            "pageid" : 2330,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1203859",
            "trainingLevel" : "Intern",
            "citation" : "Bosch J, <i>et al</i>. \"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia\". <i>The New England Journal of Medicine</i>. 2012. 367(4):309-318.",
            "subspecialties" : "Cardiology;Neurology",
            "expansion" : "Investigators in the outcome Reduction with an Initial Glargine Intervention",
            "statusUsableDate" : "2015-02-01",
            "briefResultsDescription" : "n-3 fatty acids don't reduce CVD",
            "published" : "2012-07-26",
            "pageName" : "ORIGIN n-3 Fatty Acids",
            "diseases" : "Cardiovascular Disease;Coronary Artery Disease;Stroke",
            "abbreviation" : "ORIGIN n-3 Fatty Acids",
            "title" : "n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia",
            "pmid" : "22686415"
         },
         },
         {
         {
Line 7,414: Line 7,205:
         },
         },
         {
         {
             "timestamp" : "2019-04-18T17:47:41Z",
             "timestamp" : "2025-06-19T18:35:37Z",
             "briefDesignDescription" : "Radiograph vs. MRI for low back pain",
             "briefDesignDescription" : "Radiograph vs. MRI for low back pain",
             "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/196680",
             "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/196680",
Line 7,427: Line 7,218:
             "published" : "2003-06-04",
             "published" : "2003-06-04",
             "pageName" : "Radiograph vs. MRI for low back pain",
             "pageName" : "Radiograph vs. MRI for low back pain",
             "diseases" : "Low back pain",
             "diseases" : "Low Back Pain",
             "abbreviation" : "Radiograph vs. MRI for low back pain",
             "abbreviation" : "Radiograph vs. MRI for low back pain",
             "title" : "Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.",
             "title" : "Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.",
Line 8,077: Line 7,868:
             "title" : "Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients",
             "title" : "Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients",
             "pmid" : "19188334"
             "pmid" : "19188334"
        },
        {
            "timestamp" : "2023-11-22T19:59:22Z",
            "briefDesignDescription" : "GLP-1 if prior CVD, BMI ≥27, no DM",
            "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563",
            "pageid" : 5457,
            "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2307563",
            "trainingLevel" : "student",
            "citation" : "Lincoff AM, <i>et al</i>. \"Semaglutide and cardiovascular outcomes in obesity without diabetes\". <i>The New England Journal of Medicine</i>. 2023. Epub 2023-11-11:1-12.",
            "subspecialties" : "Cardiology",
            "expansion" : "Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity",
            "statusUsableDate" : "2023-11-15",
            "briefResultsDescription" : "GLP-1 lowers CVD risk in non-diabetics with high BMI and prior CVD",
            "published" : "2023-11-11",
            "pageName" : "SELECT",
            "diseases" : "Cardiovascular disease",
            "abbreviation" : "SELECT",
            "title" : "Semaglutide and cardiovascular outcomes in obesity without diabetes",
            "pmid" : "37952131"
         },
         },
         {
         {
Line 8,552: Line 8,324:
             "title" : "Once-Weekly Semaglutide in Adults with Overweight or Obesity",
             "title" : "Once-Weekly Semaglutide in Adults with Overweight or Obesity",
             "pmid" : "33567185"
             "pmid" : "33567185"
        },
        {
            "timestamp" : "2025-06-19T18:47:05Z",
            "briefDesignDescription" : "Semaglutide in HFpEF+obesity but no DM",
            "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2306963",
            "pageid" : 5605,
            "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2306963",
            "trainingLevel" : "student",
            "citation" : "Kosiborod MN, <i>et al</i>. \"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity\". <i>The New England Journal of Medicine</i>. 2023. 389(12):1069-1084.",
            "subspecialties" : "Cardiology",
            "expansion" : "Semaglutide Treatment Effect in People with Heart Failure with Preserved Ejection Fraction",
            "statusUsableDate" : "2025-06-19",
            "briefResultsDescription" : "Semaglutide better than placebo for HF events in HFpEF+obesity",
            "published" : "2023-08-25",
            "pageName" : "STEP-HFpEF",
            "diseases" : "HFpEF;Obesity",
            "abbreviation" : "STEP-HFpEF",
            "title" : "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity",
            "pmid" : "37622681"
         },
         },
         {
         {
Line 8,668: Line 8,459:
         },
         },
         {
         {
             "timestamp" : "2020-08-10T13:30:58Z",
             "timestamp" : "2025-06-19T18:34:51Z",
             "briefDesignDescription" : "Routine PPI use in the ICU",
             "briefDesignDescription" : "Routine PPI use in the ICU",
             "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1714919",
             "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1714919",
Line 8,681: Line 8,472:
             "published" : "2018-10-24",
             "published" : "2018-10-24",
             "pageName" : "SUP-ICU",
             "pageName" : "SUP-ICU",
             "diseases" : "Stress Ulcer Prophylaxis",
             "diseases" : "Stress Ulcer",
             "abbreviation" : "SUP-ICU",
             "abbreviation" : "SUP-ICU",
             "title" : "Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU",
             "title" : "Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU",
Line 8,723: Line 8,514:
             "title" : "Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease",
             "title" : "Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease",
             "pmid" : "27959701"
             "pmid" : "27959701"
        },
        {
            "timestamp" : "2023-11-22T22:00:48Z",
            "briefDesignDescription" : "GLP-1 in DM if high CVD risk",
            "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1607141",
            "pageid" : 2882,
            "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1607141",
            "trainingLevel" : "Resident",
            "citation" : "Marso SP, <i>et al</i>. \"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2016. 375(18):1834-1844.",
            "subspecialties" : "Cardiology;Endocrinology",
            "expansion" : "Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes",
            "statusUsableDate" : "2023-11-22",
            "briefResultsDescription" : "GLP-1 lowers CVD events DM if high CVD risk",
            "published" : "2016-11-10",
            "pageName" : "SUSTAIN-6",
            "diseases" : "Diabetes Mellitus;Cardiovascular Disease",
            "abbreviation" : "SUSTAIN-6",
            "title" : "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes",
            "pmid" : "27633186"
         },
         },
         {
         {
Line 9,580: Line 9,352:
         },
         },
         {
         {
             "timestamp" : "2024-02-22T20:28:09Z",
             "timestamp" : "2025-06-19T18:34:21Z",
            "briefDesignDescription" : "Omega-3 FA for CV and cancer prevention",
            "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1811403",
            "pageid" : 4179,
            "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1811403",
            "trainingLevel" : "resident",
            "citation" : "Manson JE, <i>et al</i>. \"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer\". <i>The New England Journal of Medicine</i>. 2019. 2019(380):1.",
            "subspecialties" : "Cardiology;Oncology",
            "expansion" : "Vitamin D and Omega-3 Trial",
            "statusUsableDate" : "2024-02-22",
            "briefResultsDescription" : "Omega-3 FA did not lower CV or cancer events",
            "published" : "2019-01-03",
            "pageName" : "VITAL (Omega-3 arm)",
            "diseases" : "Cardiovascular Disease;Cancer",
            "abbreviation" : "VITAL",
            "title" : "Marine n-3 fatty acids and prevention of cardiovascular disease and cancer",
            "pmid" : "30415637"
        },
        {
            "timestamp" : "2022-12-15T19:57:40Z",
            "briefDesignDescription" : "Vitamin D for cancer or CVD prevention",
            "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa1809944",
            "pageid" : 4039,
            "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1809944",
            "trainingLevel" : "resident",
            "citation" : "Manson JE, <i>et al</i>. \"Vitamin D supplements and prevention of cancer and cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2019. 380(1):33-44.",
            "subspecialties" : "Cardiology;Oncology",
            "expansion" : "VITamin D and OmegA-3 TriaL",
            "statusUsableDate" : "2022-12-14",
            "briefResultsDescription" : "Vitamin D doesn't lower cancer or CVD risk",
            "published" : "2019-01-03",
            "pageName" : "VITAL (Vitamin D arm)",
            "diseases" : "Cardiovascular Disease;Cancer",
            "abbreviation" : "VITAL",
            "title" : "Vitamin D supplements and prevention of cancer and cardiovascular disease",
            "pmid" : "30415629"
        },
        {
            "timestamp" : "2023-11-22T21:13:36Z",
             "briefDesignDescription" : "Vitamin C, hydrocortisone, & thiamine in septic shock",
             "briefDesignDescription" : "Vitamin C, hydrocortisone, & thiamine in septic shock",
             "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.22176",
             "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.22176",
Line 9,631: Line 9,365:
             "published" : "2020-02-04",
             "published" : "2020-02-04",
             "pageName" : "VITAMINS",
             "pageName" : "VITAMINS",
             "diseases" : "Septic Shock",
             "diseases" : "Sepsis;Shock",
             "abbreviation" : "VITAMINS",
             "abbreviation" : "VITAMINS",
             "title" : "Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial",
             "title" : "Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial",
WJCBot
Bots, editor, reviewer, Administrators
13,951

edits

Retrieved from "http://www.wikijournalclub.org/wiki/Special:MobileDiff/43988"

Navigation menu